Fig. 3: Event-free survival.

Kaplan–Meier plots of event-free survival comparing ganetespib and control arms in A all HER2-negative participants, B triple negative participants, and C HR-positive/HER2-negative participants. Median follow-up in the overall (HER2-negative) population was 3.6 years.